References
- JBosch, ABerzigotti, JCGarcia-Pagan, JGAbraldes. The management of portal hypertension: rational basis, available treatments and future options. J Hepatol 2008;48:S68–92.
- VKSnowdon, NGuha, JAFallowfield. Noninvasive evaluation of portal hypertension: emerging tools and techniques. Int J Hepatol 2012;2012:691089.
- DThabut, RMoreau, DLebrec. Noninvasive assessment of portal hypertension in patients with cirrhosis. Hepatology 2011;53:683–94.
- AMGressner, RWeiskirchen. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med 2006;10:76–99.
- DSchuppan. Structure of the extracellular matrix in normal and fibrotic liver: collagens and glycoproteins. Semin Liver Dis 1990;10:1–10.
- FRuggiero, MFChampliaud, RGarrone, MAumailley. Interactions between cells and collagen V molecules or single chains involve distinct mechanisms. Exp Cell Res 1994;210:215–23.
- AFichard, JPKleman, FRuggiero. Another look at collagen V and XI molecules. Matrix Biol 1995;14:515–31.
- RJWenstrup, JBFlorer, EWBrunskill, SMBell, IChervoneva, DEBirk. Type V collagen controls the initiation of collagen fibril assembly. J Biol Chem 2004;279:53331–7.
- MAKarsdal, KHenriksen, DJLeeming, TWoodworth, EVassiliadis, ACBay-Jensen. Novel combinations of Post-Translational Modification (PTM) neo-epitopes provide tissue-specific biochemical markers--are they the cause or the consequence of the disease? Clin Biochem 2010;43:793–804.
- MAKarsdal, EDelvin, CChristiansen. Protein fingerprints - relying on and understanding the information of serological protein measurements. Clin Biochem 2011;44:1278–9.
- SMoller, LHobolth, CWinkler, FBendtsen, EChristensen. Determinants of the hyperdynamic circulation and central hypovolaemia in cirrhosis. Gut 2011;60:1254–9.
- RJGroszmann, JBosch, NDGrace, HOConn, GGarcia-Tsao, MNavasa, et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology 1990;99:1401–7.
- GGarcia-Tsao, JBosch. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med 2010;362:823–32.
- JHHenriksen, KWinkler. Hepatic blood flow determination. A comparison of 99mTc-diethyl-IDA and indocyanine green as hepatic blood flow indicators in man. J Hepatol 1987;4:66–70.
- DThabut, RMoreau, DLebrec. Noninvasive assessment of portal hypertension in patients with cirrhosis. Hepatology 2011;53:683–94.
- DThabut, RMoreau, DLebrec. Noninvasive assessment of portal hypertension in patients with cirrhosis. Hepatology 2011;53:683–94.
- LCastera, MPinzani, JBosch. Non invasive evaluation of portal hypertension using transient elastography. J Hepatol 2012;56:696–703.
- ABerzigotti, VRossi, CTiani, LPierpaoli, PZappoli, ARiili, et al. Prognostic value of a single HVPG measurement and Doppler-ultrasound evaluation in patients with cirrhosis and portal hypertension. J Gastroenterol 2011;46:687–95.
- VCalvaruso, AKBurroughs, RStandish, PManousou, FGrillo, GLeandro, et al. Computer-assisted image analysis of liver collagen: relationship to Ishak scoring and hepatic venous pressure gradient. Hepatology 2009;49:1236–44.
- SSethasine, DJain, RJGroszmann, GGarcia-Tsao. Quantitative histological-hemodynamic correlations in cirrhosis. Hepatology 2012;55:1146–53.
- KGelse, EPoschl, TAigner. Collagens--structure, function, and biosynthesis. Adv Drug Deliv Rev 2003;55:1531–46.
- DSchuppan. Structure of the extracellular matrix in normal and fibrotic liver: collagens and glycoproteins. Semin Liver Dis 1990;10:1–10.
- ONiemela, LRisteli, JParkkinen, JRisteli. Purification and characterization of the N-terminal propeptide of human type III procollagen. Biochem J 1985;232:145–50.
- WMWang, GGe, NHLim, HNagase, DSGreenspan. TIMP-3 inhibits the procollagen N-proteinase ADAMTS-2. Biochem J 2006;398:515–19.
- MAKarsdal, KHenriksen, DJLeeming, TWoodworth, EVassiliadis, ACBay-Jensen. Novel combinations of Post-Translational Modification (PTM) neo-epitopes provide tissue-specific biochemical markers--are they the cause or the consequence of the disease? Clin Biochem 2010;43:793–804.
- MJNielsen, AFNedergaard, SSun, SSVeidal, LLarsen, QZheng, et al. The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters. Am J Transl Res 2013;5:303–15.
- EVassiliadis, SSVeidal, HSimonsen, DVLarsen, BVainer, XChen, et al. Immunological detection of the type V collagen propeptide fragment, PVCP-1230, in connective tissue remodeling associated with liver fibrosis. Biomarkers 2011;16:426–33.
- EVassiliadis, SSVeidal, CHansen, MAKarsdal, DJLeeming. Circulating levels of a collagen type v propeptide fragment in a carbon tetrachloride reversible model of liver fibrosis. Biomark Insights 2012;7:159–66.
- FMal, DJHartmann, JCTrinchet, FLacombe, GVille, MBeaugrand. [Serum laminin and portal pressure in alcoholic cirrhosis. A study of 39 patients]. Gastroenterol Clin Biol 1988;12:841–4.
- AMGressner, WTittor, ANegwer, KHPick-Kober. Serum concentrations of laminin and aminoterminal propeptide of type III procollagen in relation to the portal venous pressure of fibrotic liver diseases. Clin Chim Acta 1986;161:249–58.
- AMGressner, WTittor, JKropf. The predictive value of serum laminin for portal hypertension in chronic liver diseases. Hepatogastroenterology 1988;35:95–100.
- MKondo, SJMiszputen, MMLeite-mor, ERParise. The predictive value of serum laminin for the risk of variceal bleeding related to portal pressure levels. Hepatogastroenterology 1995;42:542–5.
- JKropf, AMGressner, WTittor. Logistic-regression model for assessing portal hypertension by measuring hyaluronic acid (hyaluronan) and laminin in serum. Clin Chem 1991;37:30–5.
- DThabut, FImbert-Bismut, DCazals-Hatem, DMessous, MMuntenau, DCValla, et al. Relationship between the Fibrotest and portal hypertension in patients with liver disease. Aliment Pharmacol Ther 2007;26:359–68.
- MFerlitsch, TReiberger, MHoke, PSalzl, BSchwengerer, GUlbrich, et al. Von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis. Hepatology 2012;56:1439–47.
- DJLeeming, MAKarsdal, IByrjalsen, FBendtsen, JTrebicka, MJNielsen, et al. Novel serological neo-epitope markers of extracellular matrix proteins for the detection of portal hypertension. Aliment Pharmacol Ther 2013;38:1086–96.
- ABerzigotti, SSeijo, UArena, JGAbraldes, FVizzutti, JCGarcia-Pagan, et al. Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis. Gastroenterology 2013;144:102–11.
- JGAbraldes, IKAraujo, FTuron, ABerzigotti. Diagnosing and monitoring cirrhosis: Liver biopsy, hepatic venous pressure gradient and elastography. Gastroenterol Hepatol 2012;35:488–95.
- CBureau, SMetivier, JMPeron, JSelves, MARobic, PAGourraud, et al. Transient elastography accurately predicts presence of significant portal hypertension in patients with chronic liver disease. Aliment Pharmacol Ther 2008;27:1261–8.
- LCastera, MPinzani, JBosch. Non invasive evaluation of portal hypertension using transient elastography. J Hepatol 2012;56:696–703.
- RMalik, MLai, ASadiq, RFarnan, SMehta, INasser, et al. Comparison of transient elastography, serum markers and clinical signs for the diagnosis of compensated cirrhosis. J Gastroenterol Hepatol 2010;25:1562–8.
- MSanchez-Conde, PMiralles, JMBellon, DRincon, MRamirez, IGutierrez, et al. Use of transient elastography (FibroScan(R)) for the noninvasive assessment of portal hypertension in HIV/HCV-coinfected patients. J Viral Hepat 2011;18:685–91.
- FJanssens, Nde Suray, HPiessevaux, YHorsmans, Pde Timary, PStarkel. Can transient elastography replace liver histology for determination of advanced fibrosis in alcoholic patients: a real-life study. J Clin Gastroenterol 2010;44:575–82.